John Theurer Cancer Center Researchers Participated in ZUMA-7 Study Showing the Value of CAR T-Cell Therapy as a Second-Line Treatment for Relapsed Large B Cell Lymphoma

Newswise – HACKENSACK, NJ (DATE TK) – A new study has found that the use of CAR T cell therapy as a second line of treatment for the spread of large B cell lymphoma (DLBCL) that has come back or has continued to growing after initial treatment was more effective than the standard second-line regimen in improving event-free survival (SES / defined as disease progression, the need to start new lymphoma therapy, or death in any case). either the cause). Investigators from the John Theurer Medical Center (JTCC) at Hackensack Meridian / Hackensack University Medical Center, part of the Georgetown Lombardi Comprehensive Cancer Center, participated in the multi-center international study, called ZUMA-7.

With a median follow-up of two years, the study showed that patients with LDGCB who received a single infusion of axicabtagene ciloleucel (Yescarta®) experienced a 60% improvement in SES compared to patients who received standard care with chemotherapy and autologous stem. cell transplant. Patients in the CAR T-cell therapy group also experienced a better overall response rate. The study is continuing with additional follow-up to assess the effect of treatments on overall survival and other key parameters.

Axicabtagene ciloleucel is currently approved by the United States Food and Drug Administration for the treatment of large B cell lymphoma that comes back after or does not respond to at least two previous treatment regimens.

“This is a very exciting paradigm shift for the treatment of large B cell lymphoma,” said hematologist-oncologist Lori Leslie, MD, who led JTCC’s participation in the ZUMA-7 study. . “A 60% improvement in event-free survival is more dramatic than one might have imagined and suggests that early relapses and some patients at high risk of relapse after initial treatment may benefit from direct treatment with the cells. CAR T. ”

About 40% of patients with LDGCB will need a second treatment regimen.

CAR T-cell therapy is a form of treatment that involves removing white blood cells called T cells from the patient, modifying them in the lab to train them to see a protein (called CD19) on the lymphoma cells, and then multiply them. at a much larger size. Numbers. When delivered to the patient intravenously, they grow further, ideally identifying and killing cancer cells anywhere in the body. CAR T-cell therapy is a form of immunotherapy and has been called “living therapy” because newly formed T cells continue to find and destroy cancer cells in the body.

“As a leader in CAR T therapy, we are proud to be part of this new development in research that will continue to reshape the landscape of relapsing / refractory aggressive lymphomas that fail standard chemoimmunotherapy regimens,” said Andre Goy, MD, MS, president and executive director of the John Theurer Cancer Center.

The ZUMA-7 study began in 2017 and includes 359 patients with DLBCL in 77 medical centers around the world, 30% of whom were 65 years of age or older. The side effects observed in the study were consistent with or even more favorable than the previously established safety profile for axicabtagene ciloleucel. The use of CAR T-cell therapy as a second-line treatment has not resulted in any new safety concerns. Yescarta has been instrumental in transforming the outcome for patients with third-line LDGCB. It is likely that the paradigm will continue to evolve towards earlier timing in patients with early failures.

“The contributions that the John Theurer Cancer Center has made in identifying better therapy for lymphoma research and treatment strengthens its position as a leading center,” said Ihor Sawczuk, MD, FACS, president of the Northern Region and Research Director, Méridien Hackensack Health. “Hackensack Meridian Health is proud to have participated in this pivotal study. “

“We are committed to continuing to provide the latest research-based treatments to members of our communities,” added Mark D. Sparta, FACHE, hospital president and CEO, Hackensack University Medical Center and executive vice president of Population Health, Hackensack Meridian Health. “The John Theurer Cancer Center was the first center in New Jersey to be certified to offer CAR T cell therapy and was active in research evaluating its use long before it was first approved by the FDA. We are very happy to see these promising results, which show how this powerful immunotherapy can benefit more people. “


The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey’s best cancer center, as recognized by US News & World Report. As the state’s premier cancer center, we are also the largest and most comprehensive center dedicated to diagnosis, treatment, management, research, screening and preventive care, and survival of patients with all types of cancer. The 16 specialist divisions covering the full spectrum of cancer care have developed a tight-knit team of medical, research, nursing and support staff with specialist expertise that translates into more advanced and targeted care for all patients. Each year, more people in the New Jersey / New York metro area turn to the John Theurer Cancer Center for cancer care than any other New Jersey facility. The John Theurer Cancer Center is part of the Georgetown Lombardi Comprehensive Cancer Center, a comprehensive cancer center designated by the NCI. Housed in a 775-bed non-profit teaching, tertiary care and research hospital, the John Theurer Cancer Center offers cutting-edge technological advancements, compassionate care, research innovations, medical expertise and a full range of follow-up care. services that set the John Theurer Cancer Center apart from other institutions. For more information, please visit


Source link

Comments are closed.